Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Dalbavancin (Dalvance) vs Rezafungin (Rezzayo)
An educational, source-based comparison of Dalbavancin (Dalvance) and Rezafungin (Rezzayo) — how each peptide works, what it's researched for, and what to know before going deeper.
Long-acting lipoglycopeptide for skin and soft tissue infections.
Semi-synthetic lipoglycopeptide that binds D-Ala-D-Ala, inhibiting Gram-positive cell wall synthesis; long terminal half-life supports single- or two-dose courses.
- Acute bacterial skin and skin structure infections (ABSSSI)
- S. aureus bacteremia (investigational)
- • FDA-approved.
- • Allows outpatient single-dose treatment.
Once-weekly echinocandin for candidemia and invasive candidiasis.
Next-generation echinocandin structurally related to anidulafungin with enhanced stability, inhibiting β-(1,3)-D-glucan synthase; long half-life permits once-weekly IV dosing.
- Candidemia
- Invasive candidiasis
- • FDA-approved (2023).
- • Infusion reactions and photosensitivity reported.
Dalbavancin (Dalvance) vs Rezafungin (Rezzayo) — Key differences
- Class: Dalbavancin (Dalvance) is classified as Lipoglycopeptide · Infectious Disease, while Rezafungin (Rezzayo) is Echinocandin · Antifungal.
- Primary research focus: Dalbavancin (Dalvance) — acute bacterial skin and skin structure infections (absssi); Rezafungin (Rezzayo) — candidemia.
- Tag: FDA-Approved · Antibiotic vs FDA-Approved · Antifungal.